DWTX Stock Forecast: Dogwood Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Dogwood Therapeutics, Inc. is $15. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 71 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Dogwood Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Momentum (5): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
DWTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DWTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 27 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Apr 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DWTX.
This page is one stock. Monday covers all of them.
DWTX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
DWTX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Dogwood Therapeutics, Inc. returned −82.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
DWTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.1×
- Price / sales
- 395.7×
- Price / book
- 0.6×
- EV / EBITDA
- —
Cheaper than 96% of US stocks
Cheaper than 2% of US stocks
Cheaper than 85% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −35.6%
- Return on assets
- −13.9%
- Dividend yield
- —
Higher than 26% of US stocks
Higher than 24% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Dogwood Therapeutics, Inc. has a market value of $39.6M and an enterprise value of $34.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$36.0M.
Diluted earnings per share, trailing twelve months: −$8.95.
Free cash flow in the twelve months to 30 June 2026: −$15.1M.
Trailing P/E: 0.1×.
Dogwood Therapeutics, Inc. employs 8 people.
Data provided by Twelve Data
DWTX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at DWTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Dogwood Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about DWTX
What is the DWTX stock price forecast for 2026-2027?
The median 12-month analyst price target for Dogwood Therapeutics, Inc. is $15, with estimates ranging from $12 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DWTX stock a buy right now?
Of the 2 analysts covering Dogwood Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dogwood Therapeutics, Inc. 71 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DWTX?
As at 21 Nov 2026, Dogwood Therapeutics, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
Will DWTX stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $15, and Ticker Nerd's factor model ranks Dogwood Therapeutics, Inc. 71 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DWTX stock forecast for 2030?
No analyst covering Dogwood Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DWTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $15 over the next 12 months.
How has DWTX stock performed over the past year?
Dogwood Therapeutics, Inc. returned -82.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Dogwood Therapeutics, Inc. do?
Dogwood Therapeutics Inc. is a development-stage biopharmaceutical company focused on advancing medicines for pain and neuropathy. The company’s current pipeline centers on non-opioid therapies, including Halneuron®, a voltage-gated sodium channel modulator being developed for neuropathic pain and other pain conditions, and SP16, a cell-signaling-based program aimed at neuropathy and nerve damage.
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics Inc. is a development-stage biopharmaceutical company focused on advancing medicines for pain and neuropathy. The company’s current pipeline centers on non-opioid therapies, including Halneuron®, a voltage-gated sodium channel modulator being developed for neuropathic pain and other pain conditions, and SP16, a cell-signaling-based program aimed at neuropathy and nerve damage. Dogwood Therapeutics also works on antiviral combination therapies designed for illnesses linked to virus-triggered immune responses, including pain and fatigue-related disorders. Based in Alpharetta, Georgia, Dogwood Therapeutics operates as a single-segment company with an emphasis on clinical development, preclinical research, and targeted treatment approaches for cancer-related pain, neuropathic disorders, and related conditions.
CEO Mr. Gregory Duncan · 8 employees · United States · https://dwtx.com